{
    "nctId": "NCT00275041",
    "briefTitle": "Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Concurrent Irinotecan Plus Cetuximab in Patients With Advanced Breast Cancer With Prior Anthracycline and/or Taxane-Containing Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 21,
    "primaryOutcomeMeasure": "Confirmed tumor response (complete or partial)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Clinical manifestations of metastatic disease\n* If patient's tumor is HER2 positive (3+ by immunohistochemistry \\[IHC\\] or amplified by fluorescent in situ hybridization \\[FISH\\]), must have received at least one prior trastuzumab (Herceptin)-containing regimen unless there is a contraindication\n* Measurable disease defined as at least one lesion whose longest diameter can be accurately measured\n\n  * The only evidence of metastasis must not be bone metastases or other non-measurable disease\n  * Nonmeasurable disease is defined as all other lesions, including small lesions (longest diameter \\< 2 cm) and truly nonmeasurable lesions which include any of the following:\n\n    * Bone lesions\n    * Leptomeningeal disease\n    * Ascites\n    * Pleural/pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis/pulmonis\n    * Cystic lesions\n    * Abdominal masses that are not confirmed and followed by imaging techniques\n* No known CNS metastasis unless controlled by prior surgery and/or radiotherapy\n\n  * To be considered controlled, there must be at least 2 months of no symptoms or evidence of progression prior to study entry\n* Hormone receptor status\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\n* Men or women\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \\> 3 months\n* Hemoglobin \\> 8.0 g/dL\n* Absolute neutrophil count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin normal\n* AST and ALT \u2264 5 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must employ adequate contraception (as determined by the treating physician) during treatment and for 30 days after treatment ends\n* Disease-free for \u2265 3 years of other invasive non-breast malignancies (exception: curatively treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix)\n* No history of allergy or hypersensitivity to drug product excipients, murine antibodies, or agents chemically similar to irinotecan and/or cetuximab\n* No history or evidence of Gilbert's syndrome\n* No active, unresolved infection\n* No New York Heart Association class III or IV cardiovascular disease\n* No serious concomitant medical condition that would make it undesirable for patient to participate in the trial or would jeopardize compliance with protocol treatment\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No more than 2 prior chemotherapy regimens in the metastatic setting (irrespective of hormonal therapy or prior trastuzumab therapy)\n\n  * Prior treatment in the metastatic or adjuvant setting must have included an anthracycline or a taxane\n* No major surgery \u2264 3 weeks prior to registration\n* No chemotherapy \u2264 2 weeks prior to registration\n* No radiotherapy \u2264 4 weeks prior to registration\n* No prior irinotecan hydrochloride\n* No prior therapy with an epidermal growth factor receptor (EGFR) antagonist (either monoclonal antibody or tyrosine kinase inhibitor), such as gefitinib or erlotinib\n* No prior therapy with a dual EGFR/HER2 inhibitor (e.g., lapatinib)\n* No concurrent interleukin-11(oprelvekin)\n* Routine use of granulocyte colony stimulating factors (CSFs) is not permitted during course 1 of this study\n\n  * Subsequent use of CSFs is permitted at the discretion of the treating investigator\n* No other concurrent antitumor therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}